Cara Therapeutics Intrinsic Stock Value – CARA THERAPEUTICS Reports Q3 Earnings Results with 54.9% Decrease in Revenue for FY2023
November 21, 2023
🌥️Earnings Overview
Cara Therapeutics ($NASDAQ:CARA) revealed their Q3 earnings for FY2023 on November 13 2023, with a total revenue of USD 4.9 million, reflecting a 54.9% decrease from the same quarter in the prior year. Net income for the third quarter was USD -28.0 million, an increase from -23.2 million the year before.
Analysis – Cara Therapeutics Intrinsic Stock Value
GoodWhale’s analysis of CARA THERAPEUTICS‘s fundamentals reveals the fair value of its shares to be approximately $4.6. This value was calculated using GoodWhale’s proprietary Valuation Line. Currently, CARA THERAPEUTICS shares are trading at $1.2, resulting in a significant discount of 73.7%. This implies that CARA THERAPEUTICS is currently undervalued relative to its fair market value. Investors interested in acquiring shares of CARA THERAPEUTICS may find it to be a good investment opportunity at this time. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cara Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 21.23 | -116.52 | -549.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cara Therapeutics. More…
| Operations | Investing | Financing |
| -98.22 | 118.09 | 1.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cara Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 115.34 | 29.7 | 1.57 |
Key Ratios Snapshot
Some of the financial key ratios for Cara Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -8.3% | – | -566.3% |
| FCF Margin | ROE | ROA |
| -464.3% | -77.2% | -65.1% |
Peers
The company’s main competitors are InflaRx NV, Seagen Inc, and Mabion SA.
– InflaRx NV ($NASDAQ:IFRX)
InflaRx NV is a clinical stage biopharmaceutical company focused on leveraging the power of the body’s innate immune system to develop next-generation therapies. The company’s lead product candidate is anafilumab, a monoclonal antibody that inhibits the activity of interleukin-1 beta (IL-1β), a key driver of the inflammatory response. InflaRx is currently evaluating anafilumab in a Phase III clinical trial in patients with hidradenitis suppurativa (HS), a chronic, debilitating skin disease characterized by recurrent abscesses and scarring. If approved, anafilumab would be the first therapy specifically designed to target IL-1β in HS.
InflaRx NV has a market capitalization of 118.02 million as of 2022 and a return on equity of -24.21%. The company is focused on developing next-generation therapies that leverage the body’s innate immune system. The company’s lead product candidate is anafilumab, a monoclonal antibody that inhibits the activity of interleukin-1 beta (IL-1β). InflaRx is currently evaluating anafilumab in a Phase III clinical trial in patients with hidradenitis suppurativa (HS), a chronic, debilitating skin disease characterized by recurrent abscesses and scarring.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc is a biotechnology company that focuses on the development and commercialization of therapies for the treatment of cancer. The company has a market cap of $23.88 billion as of 2022 and a return on equity of -15.52%. Seagen Inc’s therapies are designed to target specific types of cancer, including breast, lung, and prostate cancer. The company’s products are approved for use in the United States, Europe, and Japan.
– Mabion SA ($LTS:0QGW)
Mabion SA is a Polish company that manufactures and markets biotechnology products. The company has a market cap of 329.85M as of 2022 and a return on equity of 23.01%. Mabion’s products include vaccines, blood products, and biopharmaceuticals. The company has been in operation for over 20 years and has a strong presence in Central and Eastern Europe.
Summary
Investors may have been disappointed with CARA THERAPEUTICS‘ Q3 earnings results for FY2023, which showed a 54.9% decline in total revenue compared to the same quarter last year. Net income dropped from -23.2 million in the prior year to -28.0 million. Despite these results, investors pushed the stock price up on the same day, likely due to some optimism regarding the company’s long-term prospects. It remains to be seen whether or not CARA THERAPEUTICS will be able to turn things around and deliver a positive return in future quarters.
Related Posts
Recent Posts
